Previous 10 | Next 10 |
WATERTOWN, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the Company will present at the virtual...
As the company prepares to hold its first R&D Day event today, Kymera Therapeutics (NASDAQ:KYMR) announced the addition of its newest development candidate, KT-253, targeted at liquid and solid tumors. KT-253, a selective degrader of MDM2, has the potential to become a best-in-class P53 s...
Multiple Ascending Dose (MAD) data from KT-474 Phase 1 trial demonstrates near complete IRAK4 degradation in PBMC and skin, robust ex vivo inhibition of multiple disease-relevant cytokines, and favorable safety profile KT-253, a first-in-class potent and selective MDM2 degrader target...
Two presentations demonstrated Kymera’s STAT3 degraders can reduce STAT3 expression, modify STAT3-dependent signaling, and suppress the growth of tumors in multiple preclinical models of lymphoma and solid tumors WATERTOWN, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Kymera Th...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
WATERTOWN, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of Vijay Sabesan as Sen...
Results from a phase 1 study using KT-474 in the Multiple Ascending Dose portion of data expected on R&D day Thursday, December 16th from 8:30 a.m. to 11:00 a.m. ET. KT-413 was just given IND clearance from the FDA and a phase 1 study will use the drug to target MYD88 mutant ...
Kymera Therapeutics (NASDAQ:KYMR) said the U.S. Food and Drug Administration cleared its investigational new drug (IND) application to start a clinical trial for its IRAKIMiD degrader, KT-413. “Now that the FDA has cleared our IND, we look forward to initiating our KT-413 Phase 1 ...
WATERTOWN, Mass., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the clearance of its Investigational Ne...
WATERTOWN, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced it will host a virtual R&D Day for ...
News, Short Squeeze, Breakout and More Instantly...
Kymera Therapeutics Inc. Company Name:
KYMR Stock Symbol:
NASDAQ Market:
Kymera Therapeutics Inc. Website:
2024-07-12 19:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-09 13:30:00 ET Shares of Kymera Therapeutics (NASDAQ: KYMR) were soaring 18.4% higher as of 11:28 a.m. ET on Tuesday. The big jump came after the clinical-stage biopharmaceutical company announced on Monday that its partner, Sanofi , plans to expand the ongoing phase 2 s...
WATERTOWN, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in a fireside ...